Ahmed S et al., 2021-02: Randomized double-blind placebo-controlled trial in 72 hospitalized patients in Dhaka, Bangladesh, finding faster viral clearance with five days of oral ivermectin (9.7 vs 12.7 days) and no severe adverse drug events.
Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02)
Ahmed S et al., 2021-02: Randomized double-blind placebo-controlled trial in 72 hospitalized patients in Dhaka, Bangladesh, finding faster viral clearance with five days of oral ivermectin (9.7 vs 12.7 days) and no severe adverse drug events. Randomized, double-blind, placebo-controlled trial, N=72 hospitalized adults with mild COVID-19, Dhaka, Bangladesh; three arms: ivermectin 12 mg once daily for 5 days; ivermectin 12 mg single dose plus doxycycline 200 mg then 100 mg twice daily for 4 days; placebo. Primary outcome viral clearance by RT-PCR. Result 9.7 vs 12.7 days (p=0.02) for the 5-day arm; the combination arm was not significant (11.5 days, p=0.27); fever, cough and sore throat comparable across arms. Comparator: placebo. Authors declare no known competing financial interests. No maker named. Small single-centre trial; the authors themselves call for larger trials. Study type: randomized trial.
